Thursday , July 20 2017
Home / Pulmonary Diseases

Pulmonary Diseases

Vertex Announces Positive Results for Cystic Fibrosis Triple Combos

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced positive data from Phase 1 and Phase 2 studies of three different triple combination regimens in people with cystic fibrosis (CF) who have one F508del mutation and one minimal function mutation (F508del/Min). These are the first data to demonstrate the potential to treat the underlying …

Read More »

Arena Pharmaceuticals’ Ralinepag Demonstrates Positive Results in Mid-Stage PAH Study

SAN DIEGO, July 10, 2017 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA), today announced positive Phase 2 results for ralinepag, an investigational, long-acting, orally administered prostacyclin receptor agonist under development for the treatment of pulmonary arterial hypertension (PAH).  In this 61-patient study, the primary efficacy analysis demonstrated a statistically significant absolute change from baseline in …

Read More »

Cystic Fibrosis Patients and Physicians Use Shared Decision-Making Tool to Determine Regimens

CINCINNATI–Physician-researchers at the University of Cincinnati have developed a computerized decision-making model to promote shared decision-making with cystic fibrosis patients. The tool takes into account patients’ preferences for measures of lung function and health along with the latest medical evidence for effective treatment to help patients prioritize home treatments. Mark …

Read More »

New Data Supports Potential of Catabasis’ CAT-5571 as Novel Oral Treatment for Cystic Fibrosis

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a clinical-stage biopharmaceutical company, announces positive preclinical data on CAT-5571, supporting its potential as an oral treatment for cystic fibrosis (CF). These data are being presented today at the 40th Annual European Cystic Fibrosis Society (ECFS) Conference in Seville, Spain. Patients with CF suffer …

Read More »

Two Biomarkers Appear to Predict Course of Idiopathic Pulmonary Fibrosis

ATS 2017, WASHINGTON, DC — Two T cell biomarkers appear to predict the survival trajectory of patients with idiopathic pulmonary fibrosis (IPF), a lung disease that has a varied, but ultimately devastating, impact on patients, according to new research presented at the ATS 2017 International Conference. T-cells marshal the body’s …

Read More »

FDA Expands Approval of Vertex’s Kalydeco to Treat Additional Mutations of Cystic Fibrosis

BOSTON–(BUSINESS WIRE)– Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved KALYDECO® (ivacaftor) for use in people with cystic fibrosis (CF) ages 2 and older who have one of 23 residual function mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. …

Read More »

AstraZeneca and Pieris Enter up to $2.1 Billion Deal in Respiratory Drug Collaboration

AstraZeneca today announced a strategic collaboration in respiratory diseases with Pieris Pharmaceuticals, Inc. to develop novel inhaled drugs that leverage Pieris’ Anticalin® platform. Anticalin molecules are engineered proteins which can mimic antibodies by binding to sites either on other proteins or on small molecules. They are smaller than monoclonal antibodies, offering …

Read More »

New Study Reveals Payers and Hospitals Can Save Millions in Readmission Costs, Hospitalization Rates for COPD Patients

AMSTERDAM, April 21, 2017 /PRNewswire/ — Royal Philips (NYSE: PHG, AEX: PHIA) today announced results1 from a recent study showing significant decreases in both hospital and payer costs and hospitalization rates for severe chronic obstructive pulmonary disease (COPD)2 patients. The study entitled, “Cost Savings from Reduced Hospitalizations with Use of …

Read More »

Corbus Pharmaceuticals Reports Positive Topline Data from its Cystic Fibrosis Study

NORWORD, MA — (Marketwired) — 03/30/17 — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a clinical stage drug development company targeting rare, chronic, serious inflammatory and fibrotic diseases, today announced positive topline data from its Phase 2 study evaluating multiple doses of anabasum (fka JBT-101 or Resunab) …

Read More »

Vertex’s Cystic Fibrosis Combo Meets Primary Endpoints in Two Late-Stage Studies

BOSTON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced results from two Phase 3 studies of the tezacaftor (VX-661) / ivacaftor combination treatment that showed statistically significant improvements in lung function (percent predicted forced expiratory volume in one second, or ppFEV1) in people with cystic fibrosis (CF) ages 12 and older …

Read More »